Biotech leaders: No more Covid-19 data by press release, please
A group of prominent biotech executives is asking its peers to be diligent and transparent in the process of developing treatments and vaccines for Covid-19. And when there’s data to share, describe them in detail — don’t just issue a vague press release.
As STAT’s Nicholas Florko reports, the recommendations come in an open letter organized by BIO, the industry’s largest trade group. In it, nine industry leaders lay out guiding principles for companies and regulators working as quickly as possible to advance projects that might end the pandemic.
The goal, according to BIO Chairman Jeremy Levin, is that all parties maintain the public trust, whether through diversity in clinical trials, clarity in press statements, or rigor in scientific review. Any deviations risk delegitimizing novel drugs and vaccines in the eyes of the world, which would defeat the purpose of developing them in the first place.
Read more.
As STAT’s Nicholas Florko reports, the recommendations come in an open letter organized by BIO, the industry’s largest trade group. In it, nine industry leaders lay out guiding principles for companies and regulators working as quickly as possible to advance projects that might end the pandemic.
The goal, according to BIO Chairman Jeremy Levin, is that all parties maintain the public trust, whether through diversity in clinical trials, clarity in press statements, or rigor in scientific review. Any deviations risk delegitimizing novel drugs and vaccines in the eyes of the world, which would defeat the purpose of developing them in the first place.
Read more.
.png)
No hay comentarios:
Publicar un comentario